Sarah Coseo Markt

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Jonathan J. Hue · 5 shared papers, 2021–2022 · strength 0.78
   • Paper ASO Author Reflections: Prediagnosis Weight Loss: Early Detection and Postoperative Prognosis Among Patients with Pancr… DOI 10.1245/s10434-021-09894-z↗
   • Paper Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. DOI 10.1016/j.amjsurg.2021.10.001↗
   • Paper Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant c… DOI 10.1016/j.surg.2020.12.003↗
2. Jordan Michael Winter · 5 shared papers, 2021–2022 · strength 0.78
   • Paper ASO Author Reflections: Prediagnosis Weight Loss: Early Detection and Postoperative Prognosis Among Patients with Pancr… DOI 10.1245/s10434-021-09894-z↗
   • Paper Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. DOI 10.1016/j.amjsurg.2021.10.001↗
   • Paper Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant c… DOI 10.1016/j.surg.2020.12.003↗
3. Luke Daniel Rothermel · 4 shared papers, 2021–2022 · strength 0.56
   • Paper Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. DOI 10.1016/j.amjsurg.2021.10.001↗
   • Paper Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant c… DOI 10.1016/j.surg.2020.12.003↗
   • Paper A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. DOI 10.1016/j.surg.2021.10.023↗
4. John Brian Ammori · 4 shared papers, 2021–2022 · strength 0.56
   • Paper Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. DOI 10.1016/j.amjsurg.2021.10.001↗
   • Paper Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant c… DOI 10.1016/j.surg.2020.12.003↗
   • Paper A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. DOI 10.1016/j.surg.2021.10.023↗
5. Lee Mayer Ocuin · 4 shared papers, 2021–2022 · strength 0.56
   • Paper Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. DOI 10.1016/j.amjsurg.2021.10.001↗
   • Paper Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant c… DOI 10.1016/j.surg.2020.12.003↗
   • Paper A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. DOI 10.1016/j.surg.2021.10.023↗
6. Jeffrey M. Hardacre · 4 shared papers, 2021–2022 · strength 0.56
   • Paper Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. DOI 10.1016/j.amjsurg.2021.10.001↗
   • Paper Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant c… DOI 10.1016/j.surg.2020.12.003↗
   • Paper A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. DOI 10.1016/j.surg.2021.10.023↗
7. Kavin Sugumar · 3 shared papers, 2021–2022 · strength 0.42
   • Paper Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. DOI 10.1016/j.amjsurg.2021.10.001↗
   • Paper Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant c… DOI 10.1016/j.surg.2020.12.003↗
   • Paper Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. DOI 10.1089/pancan.2021.0003↗
8. Erryk Katayama · 1 shared paper, 2022 · strength 0.13
   • Paper A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. DOI 10.1016/j.surg.2021.10.023↗
9. Mohamedraed Elshami · 1 shared paper, 2022 · strength 0.13
   • Paper A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. DOI 10.1016/j.surg.2021.10.023↗
10. David Lawrence Bajor · 1 shared paper, 2022 · strength 0.13
    • Paper A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. DOI 10.1016/j.surg.2021.10.023↗
11. Shaffer R. S. Mok · 1 shared paper, 2022 · strength 0.13
    • Paper A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. DOI 10.1016/j.surg.2021.10.023↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.